2014 · RCT

Feder et al. 2014 - ketamine for PTSD

Efficacy of intravenous ketamine for treatment of chronic PTSD

Written by: Ira ZootMedical review status: Not yet clinically reviewed.Last updated: June 4, 2026Evidence: Feder A et al.. JAMA Psychiatry, 2014.

This page has been written and edited by the publisher. It has not been reviewed by a licensed clinician.

Quick answer

Why this study matters

Opened the door for ketamine research beyond depression, particularly in trauma-related disorders.

Population

41 adults with chronic PTSD

Intervention

Single IV ketamine infusion

Comparator

Midazolam (active control)

Primary outcome

PTSD symptom severity

Key findings

Significant reduction in PTSD symptoms within 24 hours
Effect maintained over follow-up period
First randomized evidence for ketamine in PTSD

Limitations

Single dose
Modest sample
Short follow-up

Read the original study →

Disclaimer

Educational summary only. A single study - even a landmark one - does not establish clinical practice. Discuss treatment decisions with a qualified clinician.

About the author

Ira Zoot

Publisher and editor of Ketalux, based in Chicago, Illinois. Ira is a ketamine therapy patient, not a clinician. This is editorial review, not medical review: Ira is not a licensed clinician and does not provide diagnosis or medical care. Ketalux does not accept compensation from providers in exchange for favorable editorial coverage, evidence ratings, recommendations, patient referrals, or organic provider ranking. Read the full publisher disclosure →

Educational use only. The content on this page is provided for general educational purposes and does not constitute medical advice, diagnosis, or treatment. Ketamine and related therapies carry risks and are appropriate only under qualified medical supervision. Always consult a licensed healthcare professional about your individual situation. Information may change as research evolves.